Duavee vs Prempro: The Same Estrogen, Two Different Ways to Protect Your Uterus

That last rule matters more than it sounds, and we'll come back to it — because it quietly settles a question most comparison pages get wrong.

Ask about Duavee if:progestogens have made you miserable — mood, exhaustion, sore breasts, bleeding that won't settle — or you and your clinician want to avoid the progestin component. It's the only FDA-approved systemic hormone therapy for a woman with a uterus that protects the lining without a progestogen.

Ask about Prempro if:you also have vaginal dryness or painful sex (Duavee isn't approved for that), if you may need to adjust your dose (Prempro has four strengths, Duavee has one), or if progestogens have never given you trouble.

Neither is your starting point if: vaginal symptoms are your onlysymptoms, you want a patch or gel instead of a pill, you don't have a uterus, you're premenopausal, or you've had breast cancer, a blood clot, a stroke, or liver disease.

Quick comparison — the seven differences that decide most cases

What's the actual difference between Duavee and Prempro?

Both drugs contain conjugated estrogens — the same estrogen sold on its own as Premarin — and both are Pfizer portfolio products distributed by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary. The main active-ingredient difference is the component paired with that estrogen to protect the uterine lining: bazedoxifene in Duavee, medroxyprogesterone acetate in Prempro. Many of the clinical, labeling and dosing differences follow from that pairing.

That's the frame worth carrying through the whole page. Most comparisons treat these as two unrelated products with a dozen features to weigh. They aren't. Start with the pairing and the clinical picture gets a lot smaller than it felt five minutes ago.

Two honest boundaries on that framing, though. Price, formulary coverage, manufacturer programs and pharmacy stock are separate commercial variables— they don't follow from the chemistry, and we cover them separately below. And a few label differences (the age limit, the kidney note) come from what was studied, not from the molecule.

Why estrogen alone isn't enough when you still have a uterus

Systemic estrogen on its own thickens the uterine lining. Over time, that raises endometrial cancer risk.

Prempro's label puts numbers on it. In a one-year trial of Premarin 0.625 mg alone, endometrial hyperplasia showed up in 8% of evaluable biopsiesunder the consensus definition — and 20% when focal cystic hyperplasia was included. The Prempro and Premphase groups in the same trial came in at or below 1%.

We're giving you both numbers because you'll see the 20% quoted alone all over the internet, and on its own it's misleading. And it applies to that trial, that product, that dose, that duration — not to every form of unopposed estrogen ever prescribed. Duavee's hyperplasia numbers are in the same low territory. Both drugs do the job.

What bazedoxifene actually does

A SERM — selective estrogen receptor modulator — acts like estrogen in some tissues and blocksit in others. Bazedoxifene blocks estrogen in the uterine lining. That's how it does the work a progestin does in Prempro.

One precision note: Duavee is progestin-free, not “progesterone-free” in some natural-versus-synthetic sense. Bazedoxifene isn't progesterone. It isn't a progestin either. Different class entirely.

Why this matters more than it sounds

The most common thing a woman with a uterus gets told is that she has to take a progestogen. Full stop.

Duavee is the FDA-approved exception. If you've tried two or three progestogens and felt worse on every one, that exception is the difference between one more failed round and something that might actually work for you. That's who this page is for, and it's a real clinical category — not a niche.

Duavee vs Prempro: the complete label comparison

Duavee comes in one strength and is approved to treat hot flashes and prevent bone loss. Prempro comes in four strengths, adds a cyclic version called Premphase, and is additionally approved to treat vulvar and vaginal atrophy. Neither has an FDA-approved generic. Both require a prescription and are commonly filled through retail or mail-order pharmacies.

Everything below was read directly off the current FDA labels on July 28, 2026.

The one that catches people off guard

Prempro is FDA-approved for moderate-to-severe vaginal atrophy. Duavee is not.

If painful sex or vaginal dryness is part of your picture, that's a real gap — and be aware that at least one popular discount site describes Duavee as a treatment for vaginal dryness. It isn't on the label.

And here's the part almost nothing online gets right: you can't simply stack local vaginal estrogen on top of Duavee. Duavee's label says not to take additional estrogens. That general “add local to systemic” advice you'll find on plenty of menopause pages is not label-consistent for this specific drug.

The other one: Duavee has one dose, and that's the whole menu

Prempro's four strengths mean your prescriber can move you up or down. Duavee has a single strength.

If your history involves a lot of dose adjusting — you're sensitive, you've needed to titrate before, you've bounced between strengths — that asymmetry may matter to you more than anything else here.

Which one should you be asking about?

The choice comes down to two questions: can you tolerate a progestogen, and are vaginal symptoms or dose flexibility part of your picture? This section maps common situations to the label facts that govern each one. It doesn't tell you which drug to take — that's a decision for you and a prescriber who knows your history.

Has anyone actually compared Duavee and Prempro head-to-head?

Yes — at least two sponsor-run phase 3 trials did. SMART-4 and SMART-5 both compared bazedoxifene 20 mg with conjugated estrogens 0.45 mg — the marketed Duavee dose — against conjugated estrogens 0.45 mg with medroxyprogesterone acetate 1.5 mg, a marketed Prempro strength, over 12 months. SMART-5 was the larger trial and produced most of the detailed analyses. We did not identify an independent, non-sponsor replication of either.

The headline result on SMART-5's main endpoint: at 12 months, endometrial hyperplasia was under 1% and similar across all groups. Both drugs protected the lining.

Here's the detail nobody flags

Both trials compared Duavee against Prempro 0.45/1.5.

Prempro's boxed warning — the one that names breast cancer — comes from the Women's Health Initiative, which randomized women to conjugated estrogens 0.625 mg plus medroxyprogesterone 2.5 mg. A different, higher strength.

So the trials that compare these two drugs and the trial that produced the frightening warning used different versions of Prempro. That changes how you read both sets of numbers: the SMART trials describe a 12-month experience with a lower-dose Prempro, while WHI describes long-term outcomes on a higher-dose Prempro.

Four things these trials cannot tell you

We're listing these before you read anything built on them.

1. Both ran 12 months. Cancer, clots, strokes and dementia take years and far more participants.
2. They tested one Prempro strength.Results from 0.45/1.5 don't automatically transfer to 0.625/2.5 or 0.625/5.
3. The primary endpoints were endometrial safety and bone. Bleeding, breast tenderness and breast density come from secondary and companion analyses — some post hoc, meaning the question was asked after the data came in rather than planned in advance. That's weaker evidence, and we label it every time it appears below.
4. Both were manufacturer-run,inside the development program for Duavee, with sponsor-affiliated authors. That doesn't make the results wrong. It does mean an independent replication would strengthen them, and we couldn't find one.

You deserve those four before the numbers, not buried after them.

Do Duavee and Prempro have the same FDA warnings?

No. Prempro's boxed warning names breast cancer. Duavee's does not. Duavee was not studied in the Women's Health Initiative — its boxed warning cites WHI estrogen-alone class data, while Prempro's cites both the estrogen-plus-progestin and estrogen-alone WHI data. Duavee's label separately states that its effect on breast cancer risk is unknown. Both were checked against current FDA labeling on July 28, 2026.

We verified Duavee's boxed warning four separate ways — Pfizer's own medical site, the FDA's structured product label, the original FDA approval label, and DailyMed — because a finding this consequential shouldn't rest on one source.

Why the warnings differ

Prempro isthe drug WHI randomized in its estrogen-plus-progestin arm: conjugated estrogens 0.625 mg plus medroxyprogesterone 2.5 mg. When you read that boxed warning, you are reading a description of Prempro itself.

Duavee wasn't in WHI. Its warning draws on the estrogen-alone side of that trial as class information.

And Prempro's own label makes the connection

This is the part we didn't expect. From Prempro's Section 5.2:

• WHI estrogen-alone arm, 7.1 years average follow-up: conjugated estrogens alone “was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80].”
• WHI estrogen-plus-progestin arm, 5.6 years average: RR 1.24 — 41 cases versus 33 per 10,000 women per year.

Neither drug got the February 2026 labeling update

In November 2025 the FDA requested changes to menopausal hormone therapy labeling. In February 2026 it approved a first set of products.

Is Duavee safer than Prempro?

No overall safety advantage has been established. The boxed warnings differ, and that difference is real and checkable. But a boxed warning describes what has been studied and found — not everything that's true. Duavee's own label says its effect on breast cancer risk is unknown.

Prempro's breast cancer heading exists because roughly 16,600 women were randomized in WHI and followed for a mean of 5.6 years — an enormous, long-running trial built to detect outcomes like cancer.

Duavee's label says its safety was evaluated in four phase 3 trials lasting 12 weeks to 24 months, enrolling 6,210 postmenopausal women — of whom 1,224 received the marketed Duavee dose. Those trials were designed to measure hyperplasia, bone density, hot flashes and tolerability.

What about the breast density research?

A companion analysis from the SMART program (Harvey, Pinkerton and colleagues, Menopause, 2013) measured mammographic breast density. Duavee did not increase average density versus placebo at one year. The Prempro 0.45/1.5 comparator did increase it.

Breast density is a surrogate marker. A picture of tissue, not a count of cancers. Interesting, worth knowing, and not evidence of fewer cancers.

And the 2025 DCIS study?

In 2025, an ASCO meeting abstract reported a short pre-surgery “window of opportunity” biomarker trial led by Dr. Swati Kulkarni at Northwestern Medicine. Postmenopausal women with ductal carcinoma in situ were randomized to Duavee or placebo for about four weeks between diagnosis and scheduled breast surgery. 141 were enrolled, 117 completed the intervention, and 94 met the adherence and tissue criteria for the main cell-growth analysis. Investigators reported reduced breast cell proliferation versus placebo, with good tolerability.

What that study is not: a four-week biomarker study in women who already have DCIS is not a prevention trial, not an outcome trial, and hasn't changed a word of Duavee's approved uses. Genuinely interesting science. Not a reason to pick a drug.

What about clots and stroke?

Both are oral estrogen products. Both labels carry cardiovascular and clot warnings and contraindications. The SMART trials weren't large or long enough to settle which carries less risk of rare events, and the SERM component shouldn't be assumed to cancel estrogen-related clot concerns.

If you have a clot history, this comparison isn't yours. That's a contraindication on both labels.

The honest summary

Which one causes more bleeding and breast tenderness?

Duavee had the clearer advantage on both in the direct 12-month comparisons against Prempro 0.45/1.5. In SMART-5, cumulative amenorrhea — no bleeding or spotting — with both bazedoxifene/conjugated-estrogen groups was similar to placebo and to bazedoxifene alone, and significantly higher than with conjugated estrogens 0.45 mg/medroxyprogesterone acetate 1.5 mg. Breast tenderness was significantly more common on the Prempro comparator than on all other groups, while Duavee did not differ significantly from placebo.

Bleeding

Duavee didn't beat placebo on bleeding — it matchedit. That's the meaningful result: a drug delivering systemic estrogen with bleeding rates that look like taking nothing.

Duavee's own label supports the same picture from its other trials: cumulative amenorrhea at year one of 83% versus 85% on placebo in one study, and 88% versus 84% in another.

Prempro's label reports vaginal hemorrhage in 5%, 4% and 2% of women across its three lower strengths, against 0% on placebo, plus metrorrhagia and cramping at low single-digit rates.

Breast tenderness

In SMART-5, the share of women reporting at least one day of breast tenderness through 12 weeks was significantly higher on the Prempro comparator than on all other treatment groups (P<0.001). Neither Duavee dose differed significantly from placebo.

Prempro's own label is consistent. Breast pain in 26%, 20% and 13% of women across its three lower strengths, against 8% on placebo. In its other one-year trial, breast pain ran 31% to 36%.

Duavee's label doesn't list breast pain among reactions occurring in 5% or more of women at all. Its most common are muscle spasms (9%), nausea (8%), diarrhea (8%), indigestion (7%), upper stomach pain (7%), throat pain (7%), dizziness (5%) and neck pain (5%).

Endometrial protection is not the differentiator

Both drugs drive hyperplasia to roughly 1% or below. In SMART-5 the rates were under 1% and similar across every group. Both work. The question was never whetheryour lining gets protected. It's what that protection costs you — in symptoms, in flexibility, in price, in whether your plan pays.

Which works better for hot flashes?

Both are FDA-approved for moderate-to-severe hot flashes and night sweats, and both beat placebo in their own trials. Hot flashes were not a primary endpoint in the direct comparisons, so no properly powered head-to-head result exists. Their published numbers come from different trials with different baselines and different reporting methods and cannot be lined up against each other.

Prempro(HOPE study, in women with at least seven moderate-to-severe hot flushes a day): average change at week 12 of −10.82 on 0.625/2.5, −10.92 on 0.45/1.5, and −10.00 on 0.3/1.5, against −5.98 on placebo. All p<0.001. The label states there were no statistically significant differences between the three Prempro strengths at any evaluated time point.

Duavee (Study 3, 127 women versus 63 on placebo, baseline about 10.3 flushes a day): adjusted between-group difference at week 12 of −2.7 flushes per day.

Which is better for vaginal dryness or painful sex?

Prempro has an FDA-approved indication for moderate-to-severe vulvar and vaginal atrophy. Duavee does not — and Duavee's label says women taking it should not take additional estrogens, which rules out simply adding a vaginal estrogen product on top. Prempro's label says that when prescribing solely for vulvar and vaginal atrophy, topical vaginal products should be considered.

If vaginal symptoms are your only symptoms:neither pill is your first conversation. Local vaginal estrogen is lower-dose, works where you need it, and doesn't carry the same systemic considerations. Prempro's label points that direction itself. See our vaginal estrogen guide →

If you have hot flashes and vaginal symptoms: Prempro's dual indication is a genuine advantage. It's approved for both, and it doesn't close the door on a prescriber-led conversation about adding local treatment if symptoms persist.

If you want Duavee but also have vaginal symptoms: this is where you need to be careful. Duavee's label says not to add another estrogen. Do not add vaginal estrogen to Duavee based on general advice about combining local and systemic therapy — that advice exists for other regimens and doesn't transfer here. Persistent vaginal symptoms while taking Duavee call for a prescriber-led, label- consistent reassessment or a change of treatment, not a DIY add-on.

Prempro leaves the add-on conversation open. Duavee's label closes it. That's a real, decision-relevant difference that deserves more weight than the indication line alone suggests.

Which is better for preventing bone loss?

Both drugs are FDA-approved for preventing postmenopausal osteoporosis, and lumbar-spine bone density was one of SMART-5's two primary endpoints. SMART-5 found that Prempro 0.45/1.5 mg produced a greater increase in lumbar-spine bone mineral density than the Duavee groups. Both active treatments increased bone density relative to placebo. Neither trial established that either regimen prevents more fractures.

For Duavee against placebo, a pooled analysis of SMART-1 and SMART-5 gives solid figures: at 12 months, adjusted differences versus placebo were 2.3% at the lumbar spine, 1.4% at the total hip, and 1.1% at the femoral neckon conjugated estrogens 0.45 mg plus bazedoxifene 20 mg. That's a placebo comparison, and it doesn't override the direct head-to-head result above.

Bone density is not fracture prevention

Bone mineral density and fracture incidence are different endpoints. The direct Duavee-versus-Prempro trials did not establish that either regimen prevents more fractures. Both labels also say to consider non-estrogen medications when treatment is being considered solely for osteoporosis prevention.

Questions worth bringing to your appointment

• Is symptom relief also a goal, or is this only about bone?
• What is my actual fracture risk?
• Have I had a bone density scan?
• Would a non-estrogen osteoporosis drug fit better?
• How do my clot and breast history change this?

Which has more dose and route flexibility?

Prempro wins on flexibility. Four estrogen/progestin strengths plus the cyclic Premphase version, against Duavee's single fixed 0.45/20 mg strength. Both are oral tablets — neither is a patch, gel, spray, or vaginal product.

When one fixed dose is fine — and when it isn't

Fine if:you want a simple regimen, you're avoiding a progestin, and you like that the direct evidence was generated on exactly the dose you'd be taking.

Not fine if:you have a history of needing to titrate, you're dose-sensitive, or you and your prescriber want room to adjust before giving up on a drug.

If you'd rather have a patch

Neither of these is it. Both are pills. Route is a real clinical variable, not a preference detail — and if you'd rather not take an oral estrogen, that deserves its own comparison rather than being forced into this one. Just know that switching to a patch doesn't remove the uterine protection question. That still has to be solved.

Do Duavee or Prempro cause weight gain, hair loss, mood changes, or low libido?

There's no reliable head-to-head evidence establishing either drug as better for weight, hair, mood, or libido. Label-listed adverse reactions are real data; anonymous reviews claiming one drug caused a symptom are not.

Weight.Prempro's label lists weight gain at 3% across its strengths — against 4% on placebo in one trial. Neither drug should be called “weight neutral,” and neither should be sold as a weight-loss benefit. Sudden swelling or a large unexplained change is worth a call.

Hair.Prempro's label lists alopecia at 0–2%. There's no dependable basis for picking one of these drugs to prevent hair loss.

Mood.Prempro's label lists depression at 3–7% (placebo 5%) and emotional lability at 3%. Some women report mood symptoms while using a progestogen, and it comes up often in patient discussions — but we did not find a reliable estimate of how often mood symptoms actually cause someone to stop. If a progestogen made you feel unlike yourself, that's a legitimate thing to raise.

Libido. Neither drug should be sold to you as a libido treatment. Sleep, hot flash control, vaginal comfort, other medications, relationships and general health all feed into this.

How to use reviews properly: excellent for working out what to ask. Worthless for proving what's true.

Who should not take either medication?

Both labels contraindicate the same core list, including undiagnosed abnormal genital bleeding, breast cancer or a history of it, active or past blood clots, active or past stroke or heart attack, and liver disease. Duavee additionally lists pregnancy as a contraindication, is not recommended in reduced kidney function or in women over 75, and is not recommended for premenopausal use.

Leave this page if this is you

The Duavee rule you can't ignore

Don't stack. Don't overlap. Don't add progesterone because a forum said to. Don't add vaginal estrogen because another menopause page said local-plus-systemic is standard practice.

Two label details worth knowing

Thyroid.Both labels note that women on thyroid replacement may need higher doses and should have thyroid function monitored. Estrogen raises thyroid-binding globulin. If you're on levothyroxine, mention it.

Hormone testing.Both labels state that serum FSH and estradiol levels have not been shown useful in managing moderate-to-severe hot flashes. This is narrow — it doesn't mean lab testing is never appropriate for a different question — but it's a useful printed counterpoint if you've been told your levels look “normal” so nothing's wrong.

Which costs more, Duavee or Prempro?

On the discount platforms, strengths, quantities and dates shown below, listed Duavee prices were lower than listed Prempro prices. That's a dated platform comparison, not a universal retail-price rule — and note the quantities differ, so read the rows carefully.

These are prices displayed on those platforms on that date — not prices verified at a pharmacy counter. Duavee is commonly listed in 30-tablet quantities and Prempro in 28-tablet packs, so a straight side-by-side of the headline numbers slightly overstates the per-tablet gap. Prices move, vary by ZIP code, and a coupon floor is not a price anyone is guaranteed. Your pharmacy is the only authority on what you'll actually pay.

A second finding tucked in there: Drugs.com lists the same starting price for all four Prempro strengths.Stepping down a dose doesn't lower what you pay, because every strength ships as a 28-tablet pack at one price.

The savings card question — and a contradiction worth knowing about

Both drugs are Pfizer products, and there's a Pfizer menopause savings card.

What the detailed terms do state, for the products they expressly include: commercially insured patients only. Cash-paying patients are not eligible. Medicare, Medicaid, TRICARE, VA and state assistance beneficiaries are not eligible. Not redeemable more than once per 30 days. Current offers expire 12/31/2026.

And the arithmetic nobody spells out: “as little as $25” is a calculation, not a promise. With a $110 cap, $25 is only reachable if your copay is $135 or less. A $200 copay becomes $90, not $25. The card also requires commercial coverage for that drug— if your plan denies it, the card does nothing. It's a copay reducer, not a coverage substitute.

Full Duavee savings card breakdown → · Duavee cost without insurance → · 2026 HRT cost guide →

Will my insurance cover Duavee or Prempro?

Possibly the opposite of what you'd expect. On the 2026 Express Scripts National Preferred Formulary — one of the largest national templates — Duavee appears on the covered drug list while Prempro and Premphase appear on the exclusions list. Requirements vary by payer, employer plan and policy version, and your own plan document is what governs.

Read that again, because it inverts the usual assumption. The “standard” drug is excluded. The “niche” one is covered.

The caveats travel with it: the National Preferred Formulary is one template, and employers customize it. Being on the list doesn't guarantee your plan covers it. Being excluded doesn't guarantee your plan excludes it.

The contradiction worth catching early

Some written payer policies list Premphase and Prempro among the therapeutic alternatives a patient must try before Duavee is approved.

On a plan using the Express Scripts template, that step-therapy instruction can point you at a drug the same pharmacy benefit manager excludes. If that happens: it isn't your mistake, and it isn't a dead end. It's a specific, documentable argument for a formulary exception.

The documentation that may help

Some written payer policies accept a documented progestogen contraindication or intolerance as one route to Duavee approval. Requirements vary, and at least one major plan defines “intolerance” narrowly. This is the level of detail that helps:

• Product name and strength
• Dates started and stopped
• The specific reaction
• How severe, and whether it interfered with daily life or sleep
• Whether it resolved on its own
• Whether the dose was adjusted or another product tried first
• Why you stopped

Write it out before your appointment.Most of it exists nowhere except your memory, and no prescriber can document what you don't tell them.

Questions for your plan

Call the number on your card and ask, in order:

1. Is the exact strength covered?
2. What tier?
3. Does it need prior authorization?
4. Do I have to try something else first — and which drug, specifically?
5. Is mail order required?
6. Have I met my deductible?
7. What documentation does my prescriber need to submit?

Write down the rep's name and a reference number. You'll want both if you appeal.

Full Duavee coverage playbook →

Is there a generic version of Duavee or Prempro?

No FDA-approved generic was identified for either drug — unusual for two long-established products. Some pages currently advise readers to ask a pharmacist for a generic Prempro. There isn't one to ask for.

GoodRx states there are currently no generic alternatives to Prempro. Drugs.com lists it as available as a brand-name drug only. SingleCare said the same in January 2026. We're flagging the bad advice because you may have already read it, and because walking into a pharmacy to request a substitution that doesn't exist wastes a trip and can delay a fill.

What actually can lower the cost

Two separate prescriptions instead of one combination pill. A prescriber may choose separate estrogen and progestin products. Generic medroxyprogesterone is inexpensive on its own. But available standalone strengths and schedules may not reproduce your Prempro dose — this would be a different prescribed regimen, not a pharmacist-substitutable equivalent, and it needs a new prescription.

A different drug class entirely.Generic estradiol with norethindrone acetate is widely available at low cost on discount cards. Different estrogen, different progestin — not a Prempro equivalent, and not a route to progestin-free. Neither is something you can request at the counter.

Three words get used interchangeably and shouldn't be: national shortage(confirmed in the FDA's shortage database), manufacturer availability (confirmed by Pfizer), and local stock(whether your pharmacy has it today). “My pharmacy can't get it” is usually the third one. Check the FDA shortage database for national status.

Can I switch from Prempro to Duavee?

A switch should be planned by your prescriber, not improvised from something you read online. Neither label publishes a conversion schedule between these two products, and Duavee's label says not to combine it with an additional progestin, estrogen, or estrogen agonist/antagonist — so overlapping them is not an option.

We looked for a published schedule. There isn't one. So we're not inventing:

• a washout period
• an overlap period
• a “finish the pack, then start” rule
• tablet splitting or alternate-day dosing
• any method for adding progesterone or vaginal estrogen to Duavee

If you find a page offering one of those, ask where it came from.

What to ask instead

1. When do I stop the current one, and when do I start the new one?
2. Is any overlap specifically off-limits?
3. What bleeding should I report, and how fast?
4. When will we review whether it's working?
5. Does this change my breast screening or other follow-up?
6. What if the pharmacy can't fill it right away?
7. Does my plan need authorization before the switch?

And one thing to expect:bleeding patterns can change with any regimen change. Report any vaginal bleeding to your provider as soon as possible. Don't wait it out.

What should I ask before I decide?

The most useful appointment questions cover your treatment goal, uterus status, route preference, bleeding and breast history, dose flexibility, coverage, and follow-up. The goal isn't to ask which brand is “best” — it's to work out which tradeoff fits your history.

Print this. Take it with you.

1. Given my history, are both of these even appropriate for me?
2. Is my main goal hot flashes, vaginal symptoms, bone protection, or more than one?
3. Does anything in my history make an oral estrogen a bad idea?
4. What would bazedoxifene change for me compared with a progestin?
5. How much does dose flexibility matter in my case?
6. What bleeding should I expect, and when does bleeding need investigating?
7. Does my breast history or last mammogram change this decision?
8. If I take Duavee and vaginal symptoms persist, what are my label-consistent options?
9. Which exact strength does my plan cover, and does it need prior authorization?
10. When will we reassess — and how will we know if it's working?

If you've stopped progestogens before, bring the record described in the insurance section. That single sheet of paper is the most useful thing you can hand a prescriber on this topic.

Where to find a prescriber who knows this territory

Duavee and Prempro require prescriptions and are commonly filled through retail or mail-order pharmacies. What a menopause-focused clinician can do is assess whether either fits your history, document a progestogen reaction in usable detail, and request a formulary exception if your plan says no.

Who we left out, and why

Telling you this matters more than adding options.

Hersisn't here. Its published menopause menu is estradiol with progesterone — a progestogen-containing regimen, frequently the exact thing a reader on this page is trying to move away from. It's also not a route to either conjugated-estrogens product.

Winonaoffers both FDA-approved products and compounded products. Its compounded products are not FDA-approved, and we have not verified access to Duavee or Prempro through Winona, so we're not featuring it for this decision.

Inner Balance is compounded-focused, and this page is about two FDA-approved brand-name medications.

We keep those categories strictly separate on purpose. Compounded hormone products are not FDA-approved. Their quality, potency and safety are not established the way an approved product's are. They are not equivalent, not “more natural,” and not interchangeable with either drug on this page.

How we compared Duavee and Prempro

This comparison prioritizes current FDA labels, direct randomized evidence at the marketed doses, and dated commercial verification. Tolerability findings are kept separate from long-term safety conclusions throughout, because conflating the two is the most common error on this topic.

We apply The HRT Index Verification Standard— our documented process for reviewing providers: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule. We evaluate providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We don't assign numeric scores.

Who wrote this and why

Written by The HRT Index Editorial Team.This is editorial research, not clinical review — no clinician reviewed it, and we're not going to pretend otherwise by putting a name and credentials at the top.

We built it because the existing comparisons either dodge the safety question or overclaim it, and because a woman deciding between these two drugs deserves to see what the labels actually say.

What we verified — and what we didn't

Verified in primary sources on July 28, 2026

• Both boxed warnings, read directly from current FDA labeling. Duavee's confirmed across four independent sources.
• Both labels' approved uses, strengths, contraindications, adverse reaction tables and endometrial data
• Both label revision dates, and that neither drug appears on FDA's list of products already updated under the 2025–2026 labeling initiative
• SMART-4 and SMART-5 design, comparator doses, primary endpoints and sponsorship
• Duavee's stated safety database: four phase 3 trials, 6,210 women enrolled, 1,224 on the marketed dose

Accessed on third-party platforms, not verified at a pharmacy

• All cash prices, coupon floors and average retail figures in the price table, with quantities and access date shown
• Generic status, checked against three named commercial listings

Not verified, or unresolved

• Whether the Pfizer savings card currently includes Prempro. Pfizer's own page is internally inconsistent — the summary lists it, the detailed terms omit it. Unresolved, and published as unresolved.
• What your pharmacy will charge. Every price here is platform-displayed on one date.
• What your specific plan covers. Formulary templates are employer-customized.
• Whether Midi, Sesame or any listed provider specifically prescribes Duavee or Prempro, or handles prior authorizations, assistance paperwork or appeals.

What the evidence can't settle

• Both direct trials ran 12 months and were manufacturer-run, with no independent replication identified.
• Only one Prempro strength was ever compared directly — and it wasn't the strength WHI studied. Prempro's label says WHI risks should be assumed similar across doses and combinations anyway.
• Breast density is not cancer incidence. Bone density is not fractures.
• Several tolerability findings come from secondary or post hoc analyses, labeled where they appear.
• Prices, formularies and stock can change between our verification date and your appointment.

Frequently asked questions

Is Duavee the same as Prempro?

No. Both contain conjugated estrogens, but Duavee adds bazedoxifene while Prempro adds medroxyprogesterone acetate. Different approved uses, different numbers of doses, different boxed warnings.

Does Duavee contain progesterone?

No. It contains bazedoxifene, a selective estrogen receptor modulator -- not progesterone and not a progestin.

Is bazedoxifene a progestin?

No. It's a SERM, sometimes called an estrogen agonist/antagonist. It acts like estrogen in some tissues and blocks it in others.

Can I take progesterone with Duavee?

No. Duavee's label says not to take a progestin, additional estrogen, or another estrogen agonist/antagonist. Any change goes through your prescriber.

Can I use vaginal estrogen with Duavee?

Duavee's current label says women taking it should not take additional estrogens. Do not add vaginal estrogen to Duavee based on general advice about combining local and systemic therapy. If vaginal symptoms persist on Duavee, ask your prescriber what label-consistent alternative or regimen change fits your symptoms.

Did more than one trial compare Duavee with Prempro?

Yes. At least two sponsor-run phase 3 trials -- SMART-4 and SMART-5 -- compared the marketed Duavee dose with conjugated estrogens 0.45 mg/medroxyprogesterone acetate 1.5 mg over 12 months. We did not identify an independent, non-sponsor replication.

Which one is less likely to make me bleed?

Duavee, in the direct comparisons. In SMART-5, cumulative amenorrhea with the bazedoxifene/conjugated-estrogen groups was similar to placebo and to bazedoxifene alone, and significantly higher than with the Prempro 0.45/1.5 comparator. Unexplained bleeding always needs evaluating.

Is Duavee safer for the breasts?

Not established. Duavee caused significantly less breast tenderness in SMART-5 and didn't raise average mammographic density versus placebo at one year -- but Duavee's own label says its effect on breast cancer risk is unknown, and no long-term outcome trial has compared breast cancer rates between these two drugs.

Why doesn't Duavee's boxed warning mention breast cancer?

Duavee wasn't studied in WHI. Its boxed warning cites WHI estrogen-alone class data, while Prempro's cites both the estrogen-plus-progestin and estrogen-alone data -- Prempro is the drug WHI randomized. Prempro's label reports that conjugated estrogens alone were not associated with increased invasive breast cancer risk (RR 0.80), while estrogen plus progestin was (RR 1.24).

Were the boxed warnings removed in 2026?

No. As of July 28, 2026, both labels still carry their boxed warnings, and neither drug appears on FDA's list of products already updated under the 2025-2026 initiative. Prempro's DailyMed record shows an April 2026 page update while the prescribing information is marked 'Revised: 4/2025' -- two different things.

Is Duavee used in perimenopause?

Duavee has no indication for premenopausal use. Its safety and efficacy in premenopausal women have not been established, and the label says its use is not recommended.

Which is better for hot flashes?

Both are approved and both beat placebo. Hot flashes weren't a primary endpoint in the direct trials, so no proper head-to-head comparison exists, and their separate trial numbers can't be lined up.

Which is better for vaginal dryness?

Prempro is approved for vaginal atrophy; Duavee isn't -- and Duavee's label rules out adding another estrogen. If vaginal symptoms are your only symptoms, Prempro's label says topical vaginal products should be considered.

Which is better for bone?

In SMART-5, Prempro 0.45/1.5 mg produced a greater increase in lumbar-spine bone density than the Duavee groups. Both increased density versus placebo. Neither trial established that either prevents more fractures.

Does either cause weight gain?

No reliable comparative evidence. Prempro's label lists weight gain at 3%, against 4% on placebo in one trial. Don't rely on reviews to establish cause.

Is either available as a generic?

No FDA-approved generic was identified for either drug. Pages advising you to ask for a 'generic Prempro' are describing something that doesn't exist.

Can I switch straight from Prempro to Duavee?

Your prescriber sets the transition. Neither label publishes a conversion schedule, and Duavee can't be combined with a progestin or another estrogen, so don't overlap them.

Are Duavee and Prempro bioidentical?

Neither is an estradiol-plus-micronized-progesterone regimen. Compare the actual ingredients rather than treating 'bioidentical' as a safety category -- it isn't one.

The bottom line

Duavee vs Prempro isn't really a contest between two drugs. It's one question wearing a costume: do you want a progestin protecting your uterus, or a SERM?

If progestogens have gone badly for you, Duavee is the only FDA-approved systemic route that skips them while you still have a uterus — with bleeding and breast tenderness that looked like placebo in the trials that compared them. If you need dose flexibility, or vaginal symptoms are part of your picture, Prempro does things Duavee can't — including leaving the door open to a conversation Duavee's label closes. Prempro also came out ahead on spine bone density in the head-to-head.

Neither is proven safer overall. Anyone who tells you otherwise is going past the evidence.

And whichever way you're leaning: write down your progestogen history before you go. That single page does more for your odds of getting the drug you want than anything else on this one.

Sources: FDA prescribing information for Duavee and Prempro/Premphase via DailyMed and Pfizer labeling; FDA menopausal hormone therapy labeling communications and updated-prescribing- information list (November 2025 and February 2026); Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, Archer DF, SMART-5 Investigators, “Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial”; SMART-4, Climacteric2013; Pinkerton JV, Harvey JA, Pan K, et al., “Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial,” Obstetrics & Gynecology 2013;121(5):959–968; Harvey JA, Pinkerton JV, Baracat EC, et al., “Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens,” Menopause2013;20:138–45; pooled SMART-1/SMART-5 bone analysis; 2026 Express Scripts National Preferred Formulary and exclusions list; Pfizer menopause savings program terms; GoodRx, SingleCare, Drugs.com and TrumpRx listings accessed July 28, 2026; ASCO 2025 abstract and Northwestern Medicine reporting on the pre-surgical DCIS biomarker trial.

This page is educational and is not medical advice. Talk to a licensed clinician about your own situation. Last verified: July 28, 2026.